eligibility criteria for each arm is specified in the appendix and may vary depending on the intervention. as an example, eligibility criteria from the nafamostat and td139 arms has been provided: inclusion criteria: * provision of informed consent from the patient or representative * aged at least 16 years * if the patient is of child bearing potential, the patient, and their partner(s), agree to use medically-accepted double-barrier methods of contraception (eg, barrier methods, including male condom, female condom or diaphragm with spermicidal gel) during the study (if randomised to a treatment arm) and for at least 90 days after termination of study therapy. a vasectomised partner would be considered an appropriate birth control method provided that the partner is the sole male sexual partner and the absence of sperm has been confirmed. * covid-19 positive

eligibility criteria for each arm is specified in the appendix and may vary depending on the intervention. as an example, eligibility criteria from the nafamostat and td139 arms has been provided: inclusion criteria: * provision of informed consent from the patient or representative * aged at least 16 years * if the patient is of child bearing potential, the patient, and their partner(s), agree to use medically-accepted double-barrier methods of contraception (eg, barrier methods, including male condom, female condom or diaphragm with spermicidal gel) during the study (if randomised to a treatment arm) and for at least 90 days after termination of study therapy. a vasectomised partner would be considered an appropriate birth control method provided that the partner is the sole male sexual partner and the absence of sperm has been confirmed. * covid-19 positive

eligibility criteria for each arm is specified in the appendix and may vary depending on the intervention. as an example, eligibility criteria from the nafamostat and td139 arms has been provided: inclusion criteria: provision of informed consent from the patient or representative aged at least 16 years if the patient is of child bearing potential, the patient, and their partner(s), agree to use medically-accepted double-barrier methods of contraception (eg, barrier methods, including male condom, female condom or diaphragm with spermicidal gel) during the study (if randomised to a treatment arm) and for at least 90 days after termination of study therapy. a vasectomised partner would be considered an appropriate birth control method provided that the partner is the sole male sexual partner and the absence of sperm has been confirmed. covid-19 positive

eligibility criteria for each arm is specified in the appendix and may vary depending on the intervention. as an example, eligibility criteria from the nafamostat and td139 arms has been provided: inclusion criteria: provision of informed consent from the patient or representative aged at least 16 years if the patient is of child bearing potential, the patient, and their partner(s), agree to use medically-accepted double-barrier methods of contraception (eg, barrier methods, including male condom, female condom or diaphragm with spermicidal gel) during the study (if randomised to a treatment arm) and for at least 90 days after termination of study therapy. a vasectomised partner would be considered an appropriate birth control method provided that the partner is the sole male sexual partner and the absence of sperm has been confirmed. covid-19 positive

inclusion criteria: - provision of informed consent from the patient or representative - aged at least 16 years - if the patient is of child bearing potential, the patient, and their partner(s), agree to use medically-accepted double-barrier methods of contraception (eg, barrier methods, including male condom, female condom or diaphragm with spermicidal gel) during the study (if randomised to a treatment arm) and for at least 90 days after termination of study therapy. a vasectomised partner would be considered an appropriate birth control method provided that the partner is the sole male sexual partner and the absence of sperm has been confirmed. - covid-19 positive

inclusion criteria: - provision of informed consent from the patient or representative - aged at least 16 years - if the patient is of child bearing potential, the patient, and their partner(s), agree to use medically-accepted double-barrier methods of contraception (eg, barrier methods, including male condom, female condom or diaphragm with spermicidal gel) during the study (if randomised to a treatment arm) and for at least 90 days after termination of study therapy. a vasectomised partner would be considered an appropriate birth control method provided that the partner is the sole male sexual partner and the absence of sperm has been confirmed. - covid-19 positive